ANTIBODIES THAT REVERSIBLY OPEN THE BLOOD-BRAIN BARRIER

Information

  • Research Project
  • 3489648
  • ApplicationId
    3489648
  • Core Project Number
    R43AI033242
  • Full Project Number
    1R43AI033242-01
  • Serial Number
    33242
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1992 - 32 years ago
  • Project End Date
    2/28/1993 - 32 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1992 - 32 years ago
  • Budget End Date
    2/28/1993 - 32 years ago
  • Fiscal Year
    1992
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/31/1992 - 32 years ago
Organizations

ANTIBODIES THAT REVERSIBLY OPEN THE BLOOD-BRAIN BARRIER

DESCRIPTION: (Adapted from the applicant,s abstract) This research project will develop a MAb based system to reversibly permeabilize the BBB to blood- borne therapeutics. Such antibodies also may serve as carrier molecules to bring therapeutics to the BBB. To this end, a naturally occurring receptor on brain endothelium that may be involved in leukocyte migration into the brain will be examined. The presently available MAbs cross react with cerebral capillaries from human, rat, and rabbit. Preliminary studies have shown that upon intravenous injection into rabbits the antibodiesinduce transient BBB permeability and block leukocyte migration into the CSF.They demonstrate the feasibility of this approach for delivery to the brain. Phase I research will focus on a MAb that recognizes rat and human cerebral capillaries. In rat, experiments will be designed to address the following: l) time and dose dependence of antibody localization to cerebral capillaries, 2) antibody- induced transient permeability ofthe BBB to blood-borne molecules, 3) specificity for the cerebral endothelium, 4) delivery of antibody-protein conjugates to the BBB, and 5) action of antibody fragments. Additionally, isolation of the rat cerebral capillary receptor polypeptide(s) will be initiated. Phase II work will concentrate on isolation of the human receptor and development of second generation antibodies that may show increased efficacy.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    ALKERMES, INC.
  • Organization Department
  • Organization DUNS
    185481132
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024511420
  • Organization District
    UNITED STATES